Taiwan Advance Bio-Pharmaceutical Balans Gezondheid
Financiële gezondheid criteriumcontroles 2/6
Taiwan Advance Bio-Pharmaceutical has a total shareholder equity of NT$228.8M and total debt of NT$279.1M, which brings its debt-to-equity ratio to 122%. Its total assets and total liabilities are NT$699.3M and NT$470.5M respectively. Taiwan Advance Bio-Pharmaceutical's EBIT is NT$30.2M making its interest coverage ratio 5. It has cash and short-term investments of NT$138.5M.
Belangrijke informatie
122.0%
Verhouding schuld/eigen vermogen
NT$279.08m
Schuld
| Rente dekkingsratio | 5x |
| Contant | NT$138.51m |
| Aandelen | NT$228.81m |
| Totaal verplichtingen | NT$470.50m |
| Totaal activa | NT$699.32m |
Recente financiële gezondheidsupdates
Geen updates
Analyse van de financiële positie
Kortlopende schulden: 4186's short term assets (NT$242.3M) do not cover its short term liabilities (NT$284.7M).
Langlopende schulden: 4186's short term assets (NT$242.3M) exceed its long term liabilities (NT$185.8M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 4186's net debt to equity ratio (61.4%) is considered high.
Schuld verminderen: 4186's debt to equity ratio has increased from 85.2% to 122% over the past 5 years.
Schuldendekking: 4186's debt is not well covered by operating cash flow (13.1%).
Rentedekking: 4186's interest payments on its debt are well covered by EBIT (5x coverage).